e.g. mhealth
Search Results (1 to 10 of 14 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 6 Journal of Medical Internet Research
- 3 JMIR Formative Research
- 2 JMIR Dermatology
- 2 JMIR Research Protocols
- 1 JMIR Cancer
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Artificial Intelligence in Lymphoma Histopathology: Systematic Review
Lymphoma, a malignancy that originates from the lymphohematopoietic system, is recognized as one of the most prevalent hematological cancers globally. Epidemiological studies indicate that Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are prevalent malignant lymphatic disorders that pose significant public health challenges.
J Med Internet Res 2025;27:e62851
Download Citation: END BibTex RIS
These immunotherapeutic strategies have received approval for the treatment of several cancer types such as lung cancer, prostate cancer, chronic lymphocytic leukemia, and non-Hodgkin lymphoma [2]. Immunotherapy offers substantial benefits in terms of precision, specificity, and long-term survival improvements, representing a significant breakthrough in cancer treatment [3].
Immunotherapy has made remarkable progress and demonstrated clinical value.
J Med Internet Res 2025;27:e60948
Download Citation: END BibTex RIS
In the subgroup analysis for hematological malignancy subtype, no deaths were observed in the group of patients with lymphoid malignancies, including patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia. Only hematologic status (initial diagnosis, relapsed or refractory disease, stable disease, remission without therapy, or watch-and-wait strategy), Eastern Cooperative Oncology Group performance status, and ARDS were independent variables for overall survival [5].
JMIR Form Res 2023;7:e34128
Download Citation: END BibTex RIS
Inclusion criteria
Used tool: Google Trends
Health domain: solid tumor, lymphoma, leukemia, multiple myeloma, and their screening method
Language: English
Type of paper: original research, brief report, letter to the editor, etc
Exclusion criteria
Used tool: other tools related to search engines statistics than Google Trends
Health domain: not using at least one search term or topic related to malignancy or their screening method
Language: non-English
Type of paper: conference abstract
We used the Pub Med search
J Med Internet Res 2023;25:e47582
Download Citation: END BibTex RIS
From the Cochrane Library: Interventions for Mycosis Fungoides
MF remains difficult to treat despite being the most common cutaneous T cell lymphoma. The disease is often refractory, with existing treatments providing only a short duration of clinical response [1]. A 2020 Cochrane review, “Interventions for mycosis fungoides,” provides a comprehensive review of evidence from 20 randomized clinical trials of local and systemic interventions for Alibert-Bazin–type MF (N=1369) [2].
JMIR Dermatol 2022;5(3):e34448
Download Citation: END BibTex RIS
In October 2016, we drew a random sample of 523 patients with breast cancer (138/523, 26.4%), prostate cancer (125/523, 23.9%), gynecological cancer (184/523, 35.2%), or lymphoma (76/523, 14.5%) diagnosed in 4 hospitals in the period between 2014 and 2016 and who were aged ≤70 years at diagnosis. Our samples were linked with the Dutch municipal records database that contains mortality and residential data from all citizens through municipal registries to exclude all deceased patients.
JMIR Cancer 2022;8(1):e19379
Download Citation: END BibTex RIS
To investigate the effect of (1) return of individual PRO research results, including comparison with peers [24], and (2) a web-based self-management intervention Living with lymphoma, the Lymphoma Intervention (LIVE) trial was performed.
J Med Internet Res 2021;23(12):e27886
Download Citation: END BibTex RIS
This study focused on cancer survivors and their family members and friends who discussed any of the following 6 cancer conditions on Twitter in LA County (breast cancer, colon cancer, kidney cancer, lymphoma, non–small-cell lung cancer, and prostate cancer). We hypothesized that their user-generated data could be used to identify, engage, and potentially recruit cancer survivors for cancer trials.
This study relied on publicly available Twitter data.
JMIR Form Res 2021;5(11):e29958
Download Citation: END BibTex RIS
The frequencies of different types of indolent lymphomas based on the World Health Organization classification 2008 are follicular lymphoma (FL) (29%), small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) (12%), mucosal-associated lymphoid tissue lymphoma (9%), nodal marginal zone lymphoma (2%), splenic marginal zone lymphoma (0.9%), and lymphoplasmacytic lymphoma (1.4%) [1].
JMIR Form Res 2021;5(11):e24936
Download Citation: END BibTex RIS
From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis
Reassuringly, a recent 10-year prospective longitudinal study following 7954 children with atopic dermatitis who used topical tacrolimus for ≥6 weeks reported no cases of lymphoma [5].
The efficacy of tacrolimus was further substantiated with a recent 2020 study reporting that tacrolimus 0.1% was more likely to achieve clear or almost clear skin at 28 to 42 days versus vehicle (hazard ratio 1.74, 95% CI 1.13-3.05) based on the Investigator’s Static Global Assessment [6].
JMIR Dermatol 2021;4(2):e31838
Download Citation: END BibTex RIS